Clinical trials: HbA1c
Diabetes
Diabetes Multicenter Observational Study (DIAMOND-1-)
The purpose of this study is to examine whether pump treatment combined with the use of continuous glucose monitoring system is a mena to normalize glycaemic control.
- Trial name
- DIAMOND-1 (NCT01369823)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Medtronic Hellas Medical Devices ΑEE
Diabetes Mellitus
HbA1c Variation Study
To evaluate the relationship between glycated hemoglobin (HbA1c) and average glucose levels using continuous glucose monitoring.
- Trial name
- NCT05189938
- Testing
- HBA1c data and glucose levels
- Where
- 22 sites in United States, United Kingdom
- Volunteers
- 488 people
- Sponsor
- Abbott Diabetes Care
Blood Glucose, High, Oral Hypoglycaemic Overdose
Impact of Oral Glucose Tolerance Test on Extent of Hemoglobin Glycation
The glycation extent of human hemoglobin is under control of the Maillard reaction, a chemical interaction between an amino acide and a reducing sugar.
- Trial name
- HbA1c (NCT04018430)
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Urs E. Nydegger
Diabetes Mellitus, Non-Insulin-Dependent
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00039026
- Testing
- AC2993
- Where
- 126 sites in United States
- Volunteers
- 377 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c
The primary objective of this study is to evaluate whether the patients with Type 1 diabetes mellitus in sub-optimal glycemic control can achieve better glycemic control by using the Medtronic MiniMed Paradigm® REAL-Time Pump…
- Trial name
- SWITCH (NCT00598663)
- Testing
- insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System), insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)
- Where
- 8 sites in Austria, Denmark and 5 more
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Mellitus
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)
A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release (LAR) on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet…
- Trial name
- NCT00308139
- Testing
- exenatide, long acting release, exenatide
- Where
- 25 sites in United States, Canada
- Volunteers
- 303 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Non-Insulin-Dependent
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00035984
- Testing
- AC2993
- Where
- 100 sites in United States
- Volunteers
- 734 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
A Study on the Effect of 2 Pen Devices on HbA1c
The purpose of this study is to test the hypothesis that the HumaPen Memoir with memory function, when used over 24 weeks for prandial insulin injections achieves superior glycemic control, when compared to the conventional…
- Trial name
- NCT00985712
- Testing
- Insulin Lispro, Huminsulin Regular, HumaPen Memoir
- Where
- 29 sites in Germany
- Volunteers
- 263 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 1
Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes
This study is to compare metabolic control, treatment satisfaction, and quality of life during continuous subcutaneous insulin infusion (CSII ) therapy with a new insulin pump system with multiple daily injections (MDI) therapy.
- Trial name
- Insight Kids (NCT02403375)
- Testing
- Accu-Chek Insight Pump System
- Where
- 9 sites in Austria, Germany and 1 more
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00039013
- Testing
- AC2993
- Where
- 129 sites in United States
- Volunteers
- 336 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Extension Study for 2993-112
This multicenter, open-label extension study of Protocol 2993-112 is designed to assess long-term glucose control as measured by HbA1c (glycosylated hemoglobin) and to evaluate long-term safety and tolerability in subjects…
- Trial name
- NCT01789957
- Testing
- AC2993
- Where
- 226 sites in United States, Canada
- Volunteers
- 225 people
- Sponsor
- AstraZeneca